Yorifuji et al. have shown that sitagliptin, a clinically used DPP-4 inhibitor, suppresses the occurrence of CRC in T2DM mice through the GLP-1 pathway in animal studies using mice (Yorifuji et al., 2016). This evidence concerns the gene DPP4 and colorectal carcinoma.